Clinico-bacteriology and risk factors for the diabetic foot infection with multidrug resistant microorganisms in north India

Biology and Medicine

Volumn 2, Issue 4, 2010, Pages 22-34

  Zubair, Mohammad ^a   Malik, Abida ^a   Ahmad, Jamal ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Diabetic foot ulcers; Multidrug resistant organisms; Outcome; Risk factors

Indexed keywords

BACILLI (CLASS); BACTERIA (MICROORGANISMS); NEGIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 84861964802     PISSN: None     EISSN: 09748369     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Ako-Nai AK, Ikem IC, Akinloye OO, Aboderin AO, Ikem RT, Kassim OO, 2006. Characterization of bacterial isolates from diabetic foot infections in Ile-Ife, Southwestern Nigeria. The Foot, 16 (3): 158-164.
2. Anand KB, Agarwal P, Kumar S, Kapil K. 2009. Comparison of Cefoxitin disk diffusion test, oxacillin screen agar and PCR for mecA gene for detection of MRSA. Indian Journal of Medical Microbiology, 27 (1): 27-9.
3. Armstrong DG, Lipsky BA, 2004. Advances in the Treatment of Diabetic Foot Infections. Diabetes Technology and Therapeutics, 6: 167-77.
4. Babypadmini S, Appalaraju B, 2004. Extendedspectrum β -lactamases in urinary isolates of Escherichia coli and Klebsiella pneumoniae -prevalence and susceptibility pattern in a tertiary care hospital. Indian Journal of Medical Microbiology, 22: 172-4.
5. Boulton AJ, Vileikyte L, 2001. Diabetic foot problems and their management around the world, in Levin and O Neal's. The Diabetic Foot, Sixth Edition. St. Louis, MO: Mosby, 6: 261-71.
6. Chincholikar DA, Pal RB, 2002. Study of fungal and bacteriological infections of the diabetic foot. Indian Journal of Pathology and Microbiology, 45: 15-22.
7. Clinical and Laboratory Standards Institute, 2007. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement. M100-S17, vol. 27, no. 1. Wayne, PA.
8. Collee JG, Fraser AG, Marmion BP, Simmons A, 1996. Mackie and McCartney Practical Microbiology, 14th edition. London: Churchill Livingstone.
9. Peterson DL, Bonomo RA, 2005. Extended spectrum beta lactamases: a clinical update. Clinical Microbiology Review, 18(4): 657-686.
10. Eckman MH, Greenfield S, Mackey WC, Wong JB, Kaplan S, Sullivan L, Dukes L, Pauker SG, 1995. Foot infections in diabetic patients. Decision and cost-effectiveness analysis. Journal of the American Medical Association, 273: 712- 720.
11. Ensor VM, Shahid M, Evans JT, Hawkey PM, 2006. Occurrence, prevalence and genetic environment of ctx-m beta-lactamase in Enterobacteriaceae from Indian hospitals. Journal of Antimicrobial Chemotherapy, 58: 1260-1263.
12. Gadepalli R, Dhawan B, Sreenivas V, Kapil A, Ammini AC, Chaudhry RA, 2006. Clinicomicrobiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care. 29: 1727-1732.
13. Gerding DN, 1995. Foot infections in diabetic patients: the risk of anaerobes. Clinical Infectious Diseases. 20 (suppl): S283-8.
14. Goldstein EJ, Citron DM, Nesbit CA, 1996. Diabetic foot infections: bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care, 19: 638-641.
15. Hartemann-Heurtier A, Robert J, Jacqueminet S, Ha Van G, Golmard JL, Jarlier V, Grimaldi A, 2004. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. Diabetic Medicine, 21: 710-715
16. Herrero IA, Issa NC, Patel R, 2002. Nosocomial spread of linezolid resistant, vancomycin-resistant Enterococcus faecium. The New England Journal of Medicine, 346: 867-869.
17. Joshi N, Caputo G, Weitekamp M, Karchmer A, 1999. Infections in patients with diabetes mellitus. The New England journal of Medicine, 341: 1906 - 12.
18. Benjamin A, Lipsky BA, Anthony R, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, LeFrock JL, Lew DP, Mader JT, Norden C, Tan JS. 2004. Diagnosis and treatment of diabetic foot infections. Clinical Infectious Diseases, 39: 885- 910.
19. Lipsky BA, Itani K, Norden C, 2004. Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clinical Infectious Diseases. 38: 17-24.
20. Lipsky BA, Pecoraro RE, Larson SA, Hanley MA, Ahroni J, 1990. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Archives of Internal Medicine. 150: 790-797.
21. Mathur P, Tatman A, Das B, Dhavan B, 2002. Prevalence of ESBL gram-negative bacteria in a tertiary care hospital. Indian Journal of Medical Microbiology, 115: 153-7.
22. Mike E, Ali F, 2004. The use of antibiotics in the diabetic foot. American Journal of Surgery, 187: 25S- 8S.
23. Shahid M, Malik A, Adil M, Jahan N, Malik R, 2009. Comparison of beta-lactamase genes in clinical and food bacterial isolates in India. Journal of Infection in Developing Countries, 3(8): 593-598.
24. Motta RN, Oliveira MM, Magalhães PSF, Dias AM, Aragão LP, Forti AC, Carvalho CBM, 2003. Plasmid mediated extended spectrum beta-lactamase producing strains of Enterobacteriacea isolated from diabetic foot infections in Brazilian diabetic centre. Brazilian Journal of Infectious Diseases, 7: 129-34.
25. National Committee for Clinical Laboratory Standards, 2002. Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Standard. M100-S12, vol. 22, no. 1. Villanova, PA.
26. Raja NS, 2007. Microbiology of diabetic foot infections in a teaching hospital in Malaysia: a retrospective study of 194 cases. Journal of Microbiology, Immunology and Infection, 40(1): 39-44.
27. Shahid M, Ensor VM, Hawkey PM, 2009. Emergence and dissemination of Enterobacteriaceae with plasmid-mediated CMY-6 and CTX-M-15 beta-lactamases in a community in North India. World Journal of Microbiology and Biotechnology, 25: 1439-1446.
28. Shankar EM, Mohan V, Premalatha G, Srinivasan RS, Usha AR. 2005. Bacterial etiology of diabetic foot infections in South India. European Journal of Internal Medicine, 16: 567-570.
29. Shobha KL, Ramachandra L, Rao G , Majumder S, Rao SP, 2009. Extended spectrum beta-lactamases (ESBL) in gram-negative bacilli at a tertiary care hospital. Journal of Clinical and Diagnostic Research, 3: 1307-1312.
30. Tentolouris N, Jude EB, Smirnof I, Knowles EA, Boulton AJ, 1999. Methicillin resistance Staphylococcus aureus: an incereasing problem in a diabetic foot clinic. Diabetic Medicine, 16: 767-771.
31. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ, 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet, 358: 207-208.
32. Viswanathan V, Jasmine JJ, Snehalatha C, Ramachandran A. 2002. Prevalence of pathogens in diabetic foot infection in South India type 2 diabetic patients. Journal of Associations of Physicians in India, 50: 1013-6.
33. Wagner FW, 1981. The dysvascular foot: a system of diagnosis and treatment. Foot Ankle, 2: 64-122,.
34. Walsh TR, Toleman MA, Jones RN, 2007. Comment on: Occurrence, prevalence and genetic environment of CTX-M ß-lactamases in Enterobacteriaceae from Indian hospitals. Journal of Antimicrobial Chemotherapy, 60: 187-188.